Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04927234 · ClinicalTrials.gov registry record · NA

Foot and Ankle Post-operative Oedema Management Using Geko™

A NA study of Surgery and Edema, sponsored by Firstkind.

Completed
Registry status
NA
Development phase
123
Enrollment target
5
Study locations

NCT04927234: Completed NA study of Surgery and Edema, sponsored by Firstkind.

NCT04927234 is a NA study of Surgery and Edema that has completed, run by Firstkind. The registered enrollment target is 123 participants, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04927234, a NA study of Surgery and Edema, has completed, sponsored by Firstkind.

COMPLETED
Registry status
NA
Development phase
123 participants
Enrollment target
5
Study locations

Study Summary

The multicentre randomised geko™ Foot and Ankle Trial will prospectively and systematically collect clinical data on patients randomised, on a 1:1 basis, to either standard care or standard care plus geko™ therapy to assess oedema management and patient outcomes during a follow-up period of up to three months post-surgery.

Primary Outcome

To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery. This will be done using the figure of eight tape measurement method

Conditions Studied

Interventions

  • DEVICE geko™ therapy

Study Locations (5)

Other

  • Hospital Universitario Vall d'Hebron - Barcelona
  • Hospital Clinic Barcelona - Barcelona
  • Maidstone and Tunbridge Wells NHS Trust - Royal Tunbridge Wells
  • The Royal National Orthopaedic Hospital NHS Trust - Stanmore

California

  • Golden State Orthopedics and Spine - Capitola

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2022-10-07
Est. Completion 2024-08-05
Phase NA
Firstkind

3 total trials

What the finished NCT04927234 record still lists

NCT04927234 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Surgery appearing as the primary indexed condition, and to 1 intervention - of which geko™ therapy is the first listed.

NCT04927234 lists 5 locations in 2 states (Other, California).

Frequently Asked Questions

What is clinical trial NCT04927234 about?

NCT04927234 is a clinical study titled "Foot and Ankle Post-operative Oedema Management Using Geko™". The multicentre randomised geko™ Foot and Ankle Trial will prospectively and systematically collect clinical data on patients randomised, on a 1:1 basis, to either standard care or standard care plus geko™ therapy to assess oedema management and patient outcomes during a follow-up period of up to th...

What is the current status of trial NCT04927234?

This trial is currently completed. It is a NA study. The enrollment target is 123 participants. The study started on 2022-10-07. Estimated completion is 2024-08-05.

What conditions does trial NCT04927234 study?

This clinical trial studies the following conditions: Surgery, Edema.

What interventions are being tested in trial NCT04927234?

The interventions under investigation include: geko™ therapy (DEVICE).

Who is sponsoring clinical trial NCT04927234?

This trial is sponsored by Firstkind, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04927234 being conducted?

This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04927234's enrollment target sits among peer trials

123 52nd of 120 higher than 69 of 120 other Surgery trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Surgery trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05285891 · 123 participants · Phase 4

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  • NCT05334368 · 123 participants · Phase 3

    Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

  • NCT06088355 · 123 participants · NA

    Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

  • NCT06111131 · 123 participants · NA

    Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04927234, the US trial registry maintained by the National Library of Medicine. NCT04927234 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.